Skip to main content
. 2020 Dec 1;143(11):3170–3172. doi: 10.1093/brain/awaa329

Figure 1.

Figure 1

Longitudinal plasma p-tau217 data from Mattsson-Carlgren et al. (2020). Subject-specific biomarker data are shown together with main effects from linear mixed effects models, adjusted for age and sex, for p-tau217 in (A) amyloid-β-negative (Aβ−) cognitively unimpaired (CU) versus amyloid-β-positive (Aβ+) cognitively unimpaired; (B) amyloid-β-negative mild cognitive impairment (MCI) versus amyloid-β-positive MCI; and (C) MCI to Alzheimer’s disease (AD) dementia converters versus the remaining MCI population (i.e. stable MCI or ‘MCI to other dementia’ converters).